• A de Masson.
• Service de Dermatologie, Hôpital Saint-Louis, AP-HP, 1 avenue Claude Vellefaux, Paris 75010, France; INSERM U976, Institut de Recherche Saint-Louis, 1 avenue Claude Vellefaux, Paris 75010, France; Université de Paris, Paris, France. Electronic address: adele.demasson@aphp.fr.
• Presse Med. 2022 Mar 1; 51 (1): 104110.

AbstractMost cutaneous lymphomas are cutaneous T-cell lymphomas, and the most common form is mycosis fungoides. Sézary syndrome is a leukemic form of cutaneous T-cell lymphoma which is characterized by erythroderma and the presence of blood tumor cells. The only potential cure of cutaneous T-cell lymphomas remains allogeneic stem cell transplantation. However, monoclonal antibodies have led to a substantial progress in the treatment of advanced-stage cutaneous T-cell lymphomas. Some of them, such as mogamulizumab (anti-CCR4 monoclobal antibody) or brentuximab vedotin (anti-CD30 coupled to monomethylauristatin E, antibody drug conjugate) have shown efficacy in international randomized controlled studies. Lacutamab, an anti-KIR3DL2 monoclonal antibody, is currently tested in an international, prospective phase 2 trial in cutaneous T-cell lymphomas and peripheral T-cell lymphomas. Finally, immune checkpoint inhibitors have shown clinical benefit in open-label phase 2 studies in cutaneous T-cell lymphomas. This review focuses on the new biotherapies currently used in cutaneous T-cell lymphomas.Copyright © 2022 Elsevier Masson SAS. All rights reserved.

21 keywords...

hide…